Sam Yuen
Impact in
-
- Lymphoma Diagnosis and Treatment
- Dermatology top 2%
- Cutaneous lymphoproliferative disorders research
Papers in
-
- Lymphoma Diagnosis and Treatment 13
- Oncology 9
- CAR-T cell therapy research 6
- Viral-associated cancers and disorders 2
- Co-authors
- Giuseppe Gritti (3 shared papers)Max S. Topp (1 shared paper)Michael Crump (1 shared paper)Mehrdad Mobasher (1 shared paper)Elizabeth A. Punnoose (1 shared paper)James D. Hilger (1 shared paper)Pier Luigi Zinzani (1 shared paper)Chiara Rusconi (1 shared paper)
- Journals
- Blood (4 papers)Blood Advances (2 papers)American Journal of Hematology (2 papers)Hematological Oncology (2 papers)Journal of Clinical Oncology (1 paper)
- Partner nations
- AustraliaUnited StatesItaly
In The Last Decade
Sam Yuen
15 papers receiving 932 citations
Sam Yuen's Hit Papers
Peers
Comparison fields: 5 of 52
- Pathology and Forensic Medicine 606
- Dermatology 194
- Oncology 434
- Genetics 139
- Immunology 250
Countries citing papers authored by Sam Yuen
This map shows the geographic impact of Sam Yuen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sam Yuen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sam Yuen more than expected).
Fields of papers citing papers by Sam Yuen
This network shows the impact of papers produced by Sam Yuen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sam Yuen. The network helps show where Sam Yuen may publish in the future.
Co-authors
The 25 scholars most cited alongside Sam Yuen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Hit paper breakdown → | 2018 | 554 |
| 2 | The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma Hit paper breakdown → | 2021 | 178 |
| 3 | 2023 | 71 | |
| 4 | 2016 | 27 | |
| 5 | 2023 | 23 | |
| 6 | 2023 | 22 | |
| 7 | 2022 | 20 | |
| 8 | 2020 | 15 | |
| 9 | 2020 | 12 | |
| 10 | 2024 | 9 | |
| 11 | 2022 | 5 | |
| 12 | 2020 | 3 | |
| 13 | 2021 | 3 | |
| 14 | 2023 | 2 | |
| 15 | 2021 | 1 | |
| 16 | 2019 | 0 |
About Sam Yuen
Sam Yuen is a scholar working on Pathology and Forensic Medicine, Oncology, Genetics, Dermatology and Immunology, having authored 16 papers that have together received 945 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (13 papers), CAR-T cell therapy research (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Cutaneous lymphoproliferative disorders research (3 papers), Acute Myeloid Leukemia Research (2 papers), T-cell and Retrovirus Studies (2 papers), Viral-associated cancers and disorders (2 papers) and Chronic Myeloid Leukemia Treatments (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (606 citations), Dermatology (194 citations), Oncology (434 citations), Genetics (139 citations) and Immunology (250 citations). Sam Yuen has collaborated with scholars based in Australia, United States and Italy. Frequent co-authors include Giuseppe Gritti, Max S. Topp, Michael Crump, Mehrdad Mobasher, Elizabeth A. Punnoose, James D. Hilger, Pier Luigi Zinzani, Chiara Rusconi, Barbara Pro and Isabelle Fleury. Their work appears in journals such as Blood, Blood Advances, American Journal of Hematology, Hematological Oncology and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.